Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 148,036 shares of the company’s stock after selling 36,725 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ginkgo Bioworks were worth $250,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DNA. Commonwealth Equity Services LLC boosted its holdings in shares of Ginkgo Bioworks by 52.4% during the third quarter. Commonwealth Equity Services LLC now owns 369,061 shares of the company’s stock worth $668,000 after purchasing an additional 126,924 shares during the last quarter. Raymond James & Associates boosted its stake in Ginkgo Bioworks by 4.6% in the 3rd quarter. Raymond James & Associates now owns 193,589 shares of the company’s stock worth $350,000 after buying an additional 8,455 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Ginkgo Bioworks by 68.5% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 123,923 shares of the company’s stock valued at $224,000 after buying an additional 50,374 shares during the period. Stratos Wealth Partners LTD. acquired a new position in shares of Ginkgo Bioworks during the 3rd quarter valued at about $43,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Ginkgo Bioworks by 2.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 4,165,325 shares of the company’s stock worth $7,539,000 after acquiring an additional 117,893 shares during the period. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

NYSE DNA opened at $0.99 on Tuesday. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -2.10 and a beta of 1.42. Ginkgo Bioworks Holdings, Inc. has a one year low of $0.74 and a one year high of $2.55. The company’s 50 day moving average price is $1.08 and its 200 day moving average price is $1.31.

Ginkgo Bioworks (NYSE:DNA) last issued its earnings results on Thursday, February 29th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $34.76 million during the quarter, compared to analysts’ expectations of $40.37 million. During the same period in the prior year, the business posted ($0.04) EPS. The business’s revenue was down 64.6% on a year-over-year basis. Sell-side analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current fiscal year.

Analyst Ratings Changes

DNA has been the subject of a number of recent analyst reports. TD Cowen dropped their price target on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. The Goldman Sachs Group dropped their price objective on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a report on Monday, January 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Ginkgo Bioworks has a consensus rating of “Hold” and an average target price of $2.20.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Mark E. Dmytruk sold 47,806 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total value of $40,157.04. Following the completion of the sale, the insider now owns 925,400 shares of the company’s stock, valued at $777,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Mark E. Dmytruk sold 51,169 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total transaction of $53,727.45. Following the completion of the sale, the insider now directly owns 865,079 shares of the company’s stock, valued at approximately $908,332.95. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark E. Dmytruk sold 47,806 shares of Ginkgo Bioworks stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total transaction of $40,157.04. Following the sale, the insider now directly owns 925,400 shares in the company, valued at approximately $777,336. The disclosure for this sale can be found here. 15.05% of the stock is currently owned by corporate insiders.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.